Market Research Report
Epiomic Epidemiology Series: Angina Pectoris Forecast in 20 Major Markets 2018-2028
|Published by||Black Swan Analysis||Product code||339841|
|Published||Content info||68 Pages
Delivery time: 1-2 business days
|Epiomic Epidemiology Series: Angina Pectoris Forecast in 20 Major Markets 2018-2028|
|Published: August 1, 2018||Content info: 68 Pages||
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Angina Pectoris in 20 Major Markets
Angina Pectoris (AP) is the term given to the pain or discomfort felt when the heart muscle lacks an adequate supply of oxygen rich blood (ischaemia). The main cause of angina is coronary arterial disease (CAD), which is the obstruction of coronary arteries due to build up of atherosclerotic plaque. Other forms of angina include microvascular angina (MVD) also known as Cardiac Syndrome X.
This report provides the current prevalent population for AP across 20 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Ireland, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of course of progression, coronary vessels affected and associated co-morbidities of AP. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, patient parameters and co-morbidities of AP have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Chronic heart failure
Peripheral artery disease
Aortic valve sclerosis
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Ability to quantify patient populations in global AP market to target the development of future products, pricing strategies and launch plans.
Further insight into the prevalence of the subdivided types of AP and identification of patient segments with high potential.
Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
Better understanding on the impact of specific co-morbid conditions on the prevalent population of AP patients.
Identification of AP patient sub-populations that require treatment.
Better understanding of the specific markets that have the largest number of AP patients.